Home » Stocks » TCON

TRACON Pharmaceuticals, Inc. (TCON)

Stock Price: $3.81 USD -0.02 (-0.52%)
Updated Jul 29, 2021 4:00 PM EDT - Market closed
After-hours: $3.77 -0.04 (-1.05%) Jul 29, 5:10 PM
Market Cap 59.37M
Revenue (ttm) n/a
Net Income (ttm) -17.82M
Shares Out 15.50M
EPS (ttm) -1.54
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $3.81
Previous Close $3.83
Change ($) -0.02
Change (%) -0.52%
Day's Open 3.80
Day's Range 3.77 - 3.89
Day's Volume 280,201
52-Week Range 1.55 - 12.20

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer th...

1 day ago - GlobeNewsWire

SAN DIEGO, July 21, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON) (“TRACON” or the “Company”), a clinical stage biopharmaceutical company focused on the development and commercializatio...

1 week ago - GlobeNewsWire

SAN DIEGO, July 21, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON) (“TRACON” or the “Company”), a clinical stage biopharmaceutical company focused on the development and commercializatio...

1 week ago - GlobeNewsWire

SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer t...

1 week ago - GlobeNewsWire

SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer t...

4 weeks ago - GlobeNewsWire

Application Included Clinical Trial Data from Soft Tissue Sarcoma Patients Treated with Envafolimab in Phase 1 Trials

1 month ago - GlobeNewsWire

TRACON Pharmaceuticals Inc (NASDAQ:TCON) has presented updated data from its Phase 1 study of TJ004309 (uliledlimab) and Tecentriq (atezolizumab) at the American Society of Clinical Oncology (ASCO) virt...

1 month ago - Proactive Investors

SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeut...

1 month ago - GlobeNewsWire

TRACON Pharmaceuticals Inc (NASDAQ:TCON) says the Independent Data Monitoring Committee for the ENVASARC pivotal trial has recommended that the trial will proceed as planned following the review of safe...

1 month ago - Proactive Investors

Trial to Continue as Planned Trial to Continue as Planned

1 month ago - GlobeNewsWire

SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer th...

2 months ago - GlobeNewsWire

SAN DIEGO, May 20, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer th...

2 months ago - GlobeNewsWire

TRACON Pharmaceuticals Inc (NASDAQ:TCON) ended the first quarter of 2021 on March 31 with cash and equivalents of $30.4 million, which it said will fund its operations into the second half of 2022. The ...

2 months ago - Proactive Investors

SAN DIEGO, May 05, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer the...

2 months ago - GlobeNewsWire

SAN DIEGO, May 03, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer th...

2 months ago - GlobeNewsWire

SAN DIEGO, April 28, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer t...

3 months ago - GlobeNewsWire

NEW YORK, April 26, 2021 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty c...

3 months ago - PRNewsWire

Clinical-stage pipeline includes envafolimab to treat soft-tissue sarcoma Awarded Orphan Drug designation for TRC102 to treat brain and spinal cord cancers Looking for partnerships to help with regulato...

4 months ago - Proactive Investors

Poster to Highlight ENVASARC Pivotal Trial Evaluating Envafolimab in Sarcoma Poster to Highlight ENVASARC Pivotal Trial Evaluating Envafolimab in Sarcoma

4 months ago - GlobeNewsWire

SAN DIEGO, March 09, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer ...

4 months ago - GlobeNewsWire

TRACON Pharmaceuticals Inc (NASDAQ:TCON) said it has appointed Dr Lisa Johnson-Pratt to the company's board of directors. TRACON noted that Dr Johnson-Pratt brings more than two decades of broad busines...

4 months ago - Proactive Investors

SAN DIEGO, March 08, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeu...

4 months ago - GlobeNewsWire

SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer ...

4 months ago - GlobeNewsWire

SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer th...

5 months ago - GlobeNewsWire

SAN DIEGO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer th...

5 months ago - GlobeNewsWire

NDA was Submitted in November by TRACON's Corporate Partners, Alphamab Oncology and 3D Medicines, in the Indication of MSI-H/dMMR Cancer, Including Colorectal and Gastric Cancer NDA was Submitted in Nov...

6 months ago - GlobeNewsWire

SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer t...

6 months ago - GlobeNewsWire

NDA was Submitted in November in the Indication of MSI-H/dMMR Cancer, Including Colorectal and Gastric Cancer NDA was Submitted in November in the Indication of MSI-H/dMMR Cancer, Including Colorectal a...

6 months ago - GlobeNewsWire

SAN DIEGO, Dec. 29, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer t...

7 months ago - GlobeNewsWire

SAN DIEGO, Dec. 22, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer t...

7 months ago - GlobeNewsWire

Company Expects Interim Data in Mid-2021 Company Expects Interim Data in Mid-2021

7 months ago - GlobeNewsWire

Here we discuss three potential stocks that can gain following mass availability of vaccine. Vaccination may release pent-up demand across sectors.

Other stocks mentioned: ARPO, RGEN
7 months ago - Zacks Investment Research

SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer th...

8 months ago - GlobeNewsWire

Submission for Approval Filed in Indication of MSI-H/dMMR Cancer, Including Colorectal and Gastric Cancer Submission for Approval Filed in Indication of MSI-H/dMMR Cancer, Including Colorectal and Gastr...

8 months ago - GlobeNewsWire

TRACON Pharmaceuticals, Inc. (TCON) CEO Charles Theuer on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

SAN DIEGO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer th...

8 months ago - GlobeNewsWire

SAN DIEGO, Nov. 03, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer th...

8 months ago - GlobeNewsWire

SAN DIEGO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer th...

9 months ago - GlobeNewsWire

TRACON’s Pivotal ENVASARC Trial of envafolimab in the Sarcoma Subtypes of UPS and MFS Expected to Initiate Dosing in 4Q 2020 TRACON’s Pivotal ENVASARC Trial of envafolimab in the Sarcoma Subtypes of UPS...

10 months ago - GlobeNewsWire

SAN DIEGO, Sept. 10, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cance...

10 months ago - GlobeNewsWire

SAN DIEGO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cance...

10 months ago - GlobeNewsWire

SAN DIEGO, Aug. 31, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer...

10 months ago - GlobeNewsWire

SAN DIEGO, Aug. 27, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer...

11 months ago - GlobeNewsWire

Dosing in Pivotal Trial Expected to Begin in Fourth Quarter of 2020 in the U.S. Dosing in Pivotal Trial Expected to Begin in Fourth Quarter of 2020 in the U.S.

11 months ago - GlobeNewsWire

TRACON Pharmaceuticals' (TCON) CEO Charles Theuer on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

SAN DIEGO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer...

11 months ago - GlobeNewsWire

SAN DIEGO, July 29, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer ...

1 year ago - GlobeNewsWire

Dosing in Pivotal Trial Expected to Begin in Second Half of 2020 at 25 Sites in the U.S. Dosing in Pivotal Trial Expected to Begin in Second Half of 2020 at 25 Sites in the U.S.

1 year ago - GlobeNewsWire

Webinar to be held on Friday, July 17, at 11:00 AM Eastern Time Webinar to be held on Friday, July 17, at 11:00 AM Eastern Time

1 year ago - GlobeNewsWire

SAN DIEGO, June 01, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer...

1 year ago - GlobeNewsWire

About TCON

TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and age-related macular degeneration and fibrotic diseases in the United States. Its lead clinical stage product include envafolimab (KN035), an investigational PD-L1 single-domain antibody for the treatment of soft tissue sarcoma. The company's clinical stage products also include TRC102, which is a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, Phase I clini... [Read more...]

Industry
Biotechnology
IPO Date
Jan 30, 2015
Stock Exchange
NASDAQ
Ticker Symbol
TCON
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for TCON stock is "Buy." The 12-month stock price forecast is 14.57, which is an increase of 282.41% from the latest price.

Price Target
$14.57
(282.41% upside)
Analyst Consensus: Buy